Sirius is an innovative biotech company developing novel RNAi therapies for global markets. We are dedicated to providing solutions for physicians and patients to manage cardiovascular diseases. Our aim is to be a leading developer of RNAi therapeutics for the management of chronic diseases.
Sirius was founded in 2021 with a world-class leadership team and investors. After founding in 2021, Sirius established an innovation, research and development center in the United States and a translational center in China to address unmet patient needs in chronic disease. Leveraging RNAi technology, we offer a portfolio of solutions for patients to change the future of cardiovascular disease.
Completed Series B financing
Submitted the first IND to China NMPA
Established company’s new office in Shanghai,China
Completed Series A financing
Sirius China was officially established
Established US Office in Boston
Sirius US was officially established